Federated Hermes Inc. Has $680,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Federated Hermes Inc. boosted its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 245.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 153,453 shares of the company's stock after purchasing an additional 108,979 shares during the quarter. Federated Hermes Inc. owned 0.34% of Y-mAbs Therapeutics worth $680,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of YMAB. Rhumbline Advisers increased its holdings in shares of Y-mAbs Therapeutics by 4.8% during the 1st quarter. Rhumbline Advisers now owns 53,909 shares of the company's stock worth $239,000 after purchasing an additional 2,457 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Y-mAbs Therapeutics by 12.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company's stock worth $179,000 after buying an additional 2,545 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Y-mAbs Therapeutics during the fourth quarter worth about $46,000. Wells Fargo & Company MN increased its stake in Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after acquiring an additional 6,131 shares during the period. Finally, Rafferty Asset Management LLC raised its holdings in Y-mAbs Therapeutics by 17.6% in the 4th quarter. Rafferty Asset Management LLC now owns 41,255 shares of the company's stock valued at $323,000 after acquiring an additional 6,178 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock opened at $8.52 on Friday. Y-mAbs Therapeutics, Inc. has a 12-month low of $3.55 and a 12-month high of $16.11. The stock has a market capitalization of $385.79 million, a P/E ratio of -13.31 and a beta of 0.57. The company has a 50-day simple moving average of $4.87 and a 200 day simple moving average of $4.93.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. The company had revenue of $20.90 million during the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 31.84% and a negative return on equity of 30.59%. On average, equities analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on YMAB. Cantor Fitzgerald set a $8.60 price objective on Y-mAbs Therapeutics and gave the stock a "neutral" rating in a report on Tuesday. Wedbush downgraded shares of Y-mAbs Therapeutics from an "outperform" rating to a "neutral" rating and set a $8.60 price target on the stock. in a research note on Tuesday. Oppenheimer cut shares of Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Tuesday. HC Wainwright downgraded shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price objective for the stock from $11.00 to $8.60 in a report on Wednesday. Finally, Canaccord Genuity Group cut shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and lowered their target price for the company from $26.00 to $8.60 in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $11.16.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Want to see what other hedge funds are holding YMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.